BEIJING, Sept. 14, 2015 /PRNewswire/ -- Sinovac Biotech
Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical
products in China, today announced
that it has been selected by the Beijing government to be a supplier of the
seasonal influenza vaccine for its 2015 vaccination campaign.
The Beijing government plans to
order a minimum of 1.2 million doses of the seasonal flu vaccine
from four manufacturers for its 2015 campaign. The exact quantity
of doses to be ordered will depend on demand during the flu season.
During the 2014 campaign, a total of 1.37 million doses of the flu
vaccine were administered, of which Sinovac supplied 400,000 doses.
Sinovac expects to begin delivering vaccines for the 2015 tender in
the third quarter of 2015.
Mr. Weidong Yin, Chairman,
President and CEO of Sinovac, commented, "We are pleased to be
selected once again by the Beijing
government to supply seasonal flu vaccines for Beijing citizens. This vaccination campaign is
an important step in protecting geriatric and school-age
populations from influenza."
The Beijing government began
purchasing seasonal flu vaccines in 2007 to prevent and control the
spread of influenza among populations most susceptible to
complications from the virus. Each year, the Beijing government evaluates potential
suppliers on product quality, service and price, among other
factors.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacturing, and
commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against
hepatitis A and B, seasonal influenza, H5N1 pandemic influenza
(avian flu), H1N1 influenza (swine flu), mumps and canine rabies.
In 2009, Sinovac was the first company worldwide to receive
approval for its H1N1 influenza vaccine, which it has supplied to
the Chinese Government's vaccination campaign and stockpiling
program. The Company is also the only supplier of the H5N1 pandemic
influenza vaccine to the government stockpiling program. Sinovac
has filed a new drug application with the China Food & Drug
Administration for its proprietary enterovirus 71 vaccine, having
been proven effective in preventing hand, foot and mouth disease in
infants and children during its Phase III clinical trial. The
Company is currently developing a number of new products including
a Sabin-strain inactivated polio vaccine, pneumococcal
polysaccharides vaccine, pneumococcal conjugate vaccine and
varicella vaccine. Sinovac primarily sells its vaccines in
China, while also exploring growth
opportunities in international markets. The Company has exported
select vaccines to Mexico,
Mongolia, Nepal, and the
Philippines, and was recently granted a license to
commercialize its hepatitis A vaccine in Chile. For more information, please visit the
Company's website at www.Sinovac.com.
Contact
Sinovac Biotech Ltd.
Helen
Yang
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S: +1 (646) 308-1707
Email: william.zima@icrinc.com
Katherine Knight
Phone: +1 (646) 277-1276
Email: katherine.knight@icrinc.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sinovac-receives-tender-to-supply-seasonal-flu-vaccine-in-beijing-300142075.html
SOURCE Sinovac Biotech Ltd.